Long-term IMPACT data find improved survival when targeted therapies matched to tumor-specific gene mutations

June 3, 2018, University of Texas M. D. Anderson Cancer Center
Apostolia M. Tsimberidou, M.D., Ph.D. Credit: MD Anderson Cancer Center

Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival (OS) in patients with advanced disease relative to those receiving non-matched treatment (NMT), according to research from The University of Texas MD Anderson Cancer Center. The researchers also found that receiving matched targeted therapy (MTT) was an independent factor for predicting longer OS.

Long-term data from IMPACT show that the three-year OS was 15 percent in the MTT group compared to 7 percent in the NMT group. The 10-year OS was 6 percent in the MTT group, compared to 1 percent in the NMT group. Apostolia M. Tsimberidou, M.D., Ph.D., professor, Investigational Cancer Therapeutics, presented the findings on the press program at the 2018 American Society for Clinical Oncology Annual Meeting.

The study is the first and largest precision medicine trial to look at survival and has the longest follow-up of any such trial, explained Tsimberidou, IMPACT's principal investigator.

MD Anderson opened IMPACT in 2007 after her experience with the targeted therapy Gleevec showed how it changed both the treatment and survival rates for chronic myeloid leukemia (CML), once a deadly disease, she said.

"When we opened IMPACT, it was viewed as incredibly novel. Because of the variability, frequency and rarity of alterations in specific solid tumor types, it was thought it would be difficult to use molecular testing for clinical trial selection, without taking into consideration any specific characteristics," Tsimberidou said. "However, gleaning from our Gleevec-CML experience, we hypothesized that genetic and molecular analysis of solid tumors also could enable the selection of optimal therapy for patients with solid tumors."

The umbrella protocol enrolled 3,743 MD Anderson patients from 2007 to 2013. All were referred to MD Anderson's Phase I program with end-stage disease. The patients' median age was 57 years, with a range in age from 16 to 86. The ratio of women to men was 61 to 39 percent, respectively. The most common cancers treated were gastrointestinal, gynecologic, breast, melanoma and lung, with the rest being more rare types.

As expected in this population, patients were heavily pre-treated; the median number of prior therapies received was four, with some being treated with any many as 16 previous therapies, said Tsimberidou.

All 3,743 patients enrolled in IMPACT received molecular testing; 1,307 were found to have at least one molecular alteration, with 711 receiving MTT (with or without chemotherapy) and 596 receiving NMT. The majority of IMPACT participants who received MTT received an investigational drug then being tested in a clinical trial; others received an FDA-approved targeted therapy commercially approved for another indication.

In those who received MTT, the median PFS was 4 months and the median OS was 9.3 months, compared to 2.8 months and 7.3 months, respectively, in those who received NMT.

Given the quantity of patients enrolled and the length of follow-up, the MD Anderson researchers were able to analyze the different pathways that predicted response in the MTT groups.

Given the number of patients in the trial and the length of follow-up, the investigators were able to develop a prognostic score to predict OS. Taking into consideration all baseline characteristics in the 1,307 patients who received molecular testing, the absence of liver metastases, normal LDH levels, normal functional status, albumin levels and platelet counts were all found to be independent factors for longer OS. Most interestingly, said Tsimberidou, receiving MTT was also found to be an independent factor associated with longer OS.

In contrast, shorter survival was associated with liver metastases, elevated LDH levels, poor functional status, low albumin levels, elevated platelet counts, and age 60 years or older. In addition, molecular alterations in the PI3K/AKT/mTOR pathway were an independent factor predicting shorter overall survival compared to other alterations.

When type of therapy was added to the model, NMT was found to be an independent factor predicting shorter survival, said Tsimberidou.

IMPACT's follow-up study, IMPACT2, is a randomized Phase II looking at PFS and is ongoing. Tsimberidou noted that the advances from IMPACT to IMPACT2, like next-generation sequencing technologies, and the use of immune features and new drugs, including immunotherapy, are staggering.

"When IMPACT first opened, we tested for no more than one-to-two genes," she said. "Now patients are being tested for hundreds of actionable genes, amplifications and mutations, as well as for immune markers. Ideally, in the future, patients' tumor testing and cell-free DNA analysis will become the standard of care at the time of diagnosis, in hopes of making a difference for upfront, especially in those with hard-to-treat cancers."

The study was supported by philanthropy funds from: Mr. Alberto Barretto, Jamie's Hope, Mr. and Mrs. Zane W. Arrott, and Mr. Steven McKenzie. Tsimberidou will present the study in full in a poster session on June 4, 2018. Tsimberidou serves as a consultant to Roche, Europe.

Explore further: Matching targeted therapies to tumor's specific gene mutations key to personalized cancer treatment

Related Stories

Matching targeted therapies to tumor's specific gene mutations key to personalized cancer treatment

June 3, 2011
(Medical Xpress) -- Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted ...

Routine genomic testing is feasible, but only a subset of patients benefit

June 5, 2017
Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some ...

Precision oncology in advanced cancer patients improves overall survival

March 12, 2018
The use of advanced molecular diagnostic technologies, such as Next-Generation Sequencing based gene panel testing, to select targeted therapies in advanced cancer patients is known as precision oncology.

Selective inhibitor shows early promise in patients with RET-altered cancers

April 16, 2018
BLU-667, a next-generation inhibitor that selectively targets the oncogenic receptor tyrosine kinase RET, was well tolerated and had broad clinical benefit in patients with advanced cancer that had progressed on previous ...

Targeted therapies selected based on multigene panel improved outcomes for patients with hard-to-treat cancers

April 3, 2017
The progression-free survival rate (PFS) in cancer patients treated with targeted therapies (identified using a multigene panel test on their tumor samples) was significantly higher than the PFS in these patients when they ...

Small-cell lung cancer patients face barriers to receiving standard-of-care treatment

January 4, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients ...

Recommended for you

A molecule for fighting muscular paralysis

November 19, 2018
Myotubular myopathy is a severe genetic disease that leads to muscle paralysis from birth and results in death before two years of age. Although no treatment currently exists, researchers from the University of Geneva (UNIGE), ...

Use genetic data to predict the best time of day to give radiotherapy to breast cancer patients, say researchers

November 19, 2018
A new clinical study led by the University of Leicester and conducted in the HOPE clinical trials facility at Leicester's Hospitals has revealed the pivotal role that changing the time of day that a patient receives radiotherapy ...

New dual-action cancer-killing virus

November 19, 2018
Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

New blood test detects early stage ovarian cancer

November 19, 2018
Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer—a disease which kills over 1000 Australian women and 150,000 globally each ...

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.